---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000148"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:11:39.448987+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Editas reports in vivo proof-of-concept for EDIT-401 with ≥90% LDL-C reduction in NHPs

## Summary
- EDIT-401 achieved ≥90% mean LDL-C reduction in non-human primates within 48 hours of a single dose.
- Same ≥90% LDL-C reduction observed in mice with high baseline LDL-C and reduced LDLR function.
- LDL-C reductions maintained in mouse models over a three-month study.
- ≥6-fold mean increase in LDLR protein in NHP liver, requiring only moderate functional editing of LDLR alleles.
- Data presented at ESGCT 32nd Annual Congress; no financial guidance or regulatory milestones changed.

## SEC filing metadata
- accession: 0001650664-25-000148
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000148/0001650664-25-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000148/edit-20251009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000148
- JSON: https://secwatch.observer/filing/0001650664-25-000148.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.